In the United States, the most common cancer for men is prostate cancer (PC), which accounts for 9% of all cancer-related deaths in men ([@bib22]). In the United Kingdom, the life-time risk of being diagnosed with PC is 1 in 10 ([@bib4]). Although PC has a favourable prognosis if detected at an early stage, it is generally incurable in patients with metastatic disease. Hormone therapy reduces androgen levels, providing rapid disease control, but patients with metastatic PC often become resistant to this treatment and develop castration-resistant PC (CRPC). Several treatment options are available to these patients, with docetaxel being the current standard of care, but in general these treatments provide only temporary disease control ([@bib17]; [@bib20]; [@bib7]; [@bib16]).

Epothilones are a novel alternative class of tubule-binding compounds with a similar mode of action to that of taxanes ([@bib2]; [@bib1]). However, unlike taxanes, epothilones can retain activity in multidrug-resistant cancer cells that overexpress the P-glycoprotein efflux pump ([@bib2]). Ixabepilone, a half-synthetic analogue of epothilone B, has demonstrated encouraging prostate-specific antigen (PSA) response rates in chemotherapy-naïve patients with advanced PC ([@bib8]; [@bib12]). Neutropenia and neuropathy were reported as grade 3 or 4 adverse events (AEs) in both studies.

Sagopilone (ZK-EPO; Bayer HealthCare Pharmaceuticals, Berlin, Germany) is the first fully synthetic member of the novel epothilone class of microtubule stabilisers and is not associated with multidrug resistance ([@bib13]). Preclinical studies demonstrated the anticancer activity of sagopilone in many human cancer xenograft models, including PC models and taxane-resistant models ([@bib10]). Compared with taxanes, sagopilone had greater cellular uptake, with no recognition by efflux mechanisms, and enhanced intrinsic activity in preclinical systems ([@bib10]). In phase I and II clinical studies, sagopilone (as a monotherapy or in combination with carboplatin or cisplatin) was well tolerated and demonstrated clinical benefit in several solid tumour types ([@bib18]; [@bib9]; [@bib14]; [@bib23]; [@bib19]).

The single-arm, multicentre, phase II study reported here investigated the efficacy and safety of sagopilone in chemotherapy-naïve patients with CRPC.

Methods
=======

Study design and objectives
---------------------------

This was a prospective, single-arm, multicentre, phase II study conducted at 18 trial sites in the USA and Argentina. A Simon two-stage (optimal) design was used. At least 3 out of the first 13 patients needed to achieve a PSA 50% response (⩾50% reduction compared with study baseline and maintained for ⩾28 days) in stage 1 for recruitment to continue until a target of 46 fully evaluable patients had been reached. Based on standards available at the time of study design, the study outcome would be considered positive if a PSA response was observed in at least 28% of patients (13 out of 46).

The primary efficacy end point was the proportion of patients with a PSA response. Secondary efficacy end points were: objective response and duration of objective response according to modified Response Evaluation Criteria in Solid Tumours (modRECIST; only in patients with measurable disease); time to progression (TTP); time to PSA response; duration of PSA response; progression-free survival (PFS); overall survival; safety; and tolerability.

Patients received one dose of 16 mg m^−2^ sagopilone intravenously over 3 h once every 3 weeks, plus 5 mg oral prednisone twice daily, for two to six cycles. Patients subsequently demonstrating a sustained clinical benefit could receive extended therapy. Study medication was permanently discontinued if patients developed grade 3 or 4 neurotoxicity or grade 3 or 4 drug-related toxicities that did not resolve within 5 weeks of the last infusion, or any grade 4 non-haematological toxicity.

This study met all local legal and regulatory requirements, followed the Declaration of Helsinki and conformed to Good Publication Practice guidelines. The protocol was approved by an independent ethics committee at each study centre. All patients provided written, informed consent before enrolment into the study.

Patients
--------

All patients (aged ⩾18 years) had histologically or cytologically confirmed metastatic adenocarcinoma of the prostate and had received no prior chemotherapy. All patients had progressive disease as demonstrated by a PSA increase on two or more consecutive measurements taken at least 7 days apart. The last PSA measurement had to be ⩾50% more than the lowest value achieved under the most recent prior treatment, with a minimal value of ⩾5 ng ml^−1^. For patients undergoing 4--6 weeks of washout from anti-androgen treatment, the post-washout PSA level had to remain elevated. Other inclusion criteria included: a World Health Organization performance status of 0--2; adequate function of the major organs; and serum testosterone levels \<50 ng ml^−1^. In addition, all patients had to have recovered adequately from previous surgery and/or radiation.

Exclusion criteria were: any prior chemotherapy for PC; use of any investigational drug within 4 weeks or five half-lives before the start of study medication; previous symptomatic brain metastases requiring whole-brain irradiation; active infection; and any concurrent malignancy other than non-melanoma skin cancer.

Patients were withdrawn from the study if they had: disease progression; unacceptable toxicity; a delay in treatment of \>2 weeks; dose postponement more than twice during the study owing to toxicities; or concurrent conditions that precluded continuing study medication.

Assessments
-----------

The primary end point of PSA response was defined as a decrease of ⩾50% compared with study baseline, with the response maintained for at least 28 days. Measurable lesions were defined by a diameter of ⩾20 mm using conventional techniques or ⩾10 mm with spiral computed tomography scan. Patients with measurable disease were evaluated by magnetic resonance imaging or computed tomography scan every two cycles and responses were assessed according to modRECIST (modified from [@bib21]) to include the category of 'unknown\' as a further possible outcome of tumour evaluation: 'unknown\' indicates that the target or non-target lesion response is unknown and no new lesions have been documented). Bone metastases were assessed at baseline, with further evaluation based on investigator-determined need and not mandated by the protocol.

The secondary end points were: duration of PSA response, defined as the time from initial PSA response to first PSA progression; time to PSA progression, defined as the time from enrolment into the study to first PSA progression; TTP, defined as the time from enrolment to progression (according to PSA criteria or modRECIST) or death from tumour; overall PFS, defined as the time from enrolment to first progression (by PSA criteria or modRECIST) or death; and overall survival, defined as the time from enrolment until death from any cause or date of last follow-up.

Adverse events and serious AEs (SAEs) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v 3.0. Standard laboratory assessments, such as serum chemistry, haematology, coagulation and urinalysis, were performed at the individual study centres.

Statistical analysis
--------------------

The primary efficacy analysis was designed to investigate the null hypothesis that the PSA response rate was ⩽0.20, *vs* an alternative hypothesis that the PSA response rate was \>0.20 (with one-sided type 1 error rate of 0.10). A Simon two-stage design minimised the number of exposed patients in case of insufficient efficacy; based on this design, the study had a planned sample size of 46 evaluable patients.

An interim analysis was planned based on the results of the first 13 evaluable patients. If there were fewer than three PSA responders, the study would be discontinued. Otherwise, the final analysis would be based on the first 46 evaluable patients. The null hypothesis would be rejected only if ⩾13 PSA responders were identified.

The primary end point was assessed using the primary analysis set. For stage 1 this included the first 13 per protocol (PP) patients (i.e., all patients assigned to study treatment with no major protocol deviation) for whom the primary efficacy variable was assessable, and for stage 2 this included the next 33 PP patients for whom the primary efficacy variable was assessable. Additionally, the primary efficacy variable was assessed descriptively for the PP set, which included all full analysis set patients assigned to study treatment without major protocol deviation. All secondary efficacy variables were analysed in the PP set. Safety analyses were investigated using the safety analysis set, which included all patients in the full analysis set with at least one intake of the study medication.

Demographic and baseline characteristics, safety end points, and clinical laboratory evaluations were analysed by descriptive statistics and/or frequency tables where appropriate. Secondary time-to-event efficacy end points were analysed using the Kaplan--Meier estimates and corresponding graphs, and other secondary efficacy end points were analysed descriptively.

Results
=======

Between August 2006 and May 2008, 70 patients were screened for inclusion in this study; 53 patients were enroled and received at least two cycles of study medication. Patient numbers were not equally distributed across sites (competitive accrual; 1--11 patients were accrued per site). Patient demographics and baseline disease characteristics are shown in [Table 1](#tbl1){ref-type="table"}. All 53 patients were included in the safety analyses, while 5 patients were excluded from the efficacy analysis: 2 did not meet all eligibility criteria and 3 were missing a baseline PSA assessment.

A median of five treatment cycles per patient were administered, with an individual median dose of 16 mg m^−2^ (range 11.8--16.0 mg m^−2^). The individual mean dose during the first six cycles was 15.1±1.4 mg m^−2^ (range 11.8--16.0 mg m^−2^) and the mean dose intensity (individual mean dose divided by planned dose according to the assigned treatment group) was 94±9%.

The median duration for which patients remained on the study, from start of study to end of any follow-up, was 190 days (interquartile range 122--247 days). The median follow-up time, from last study medication to last clinic visit, was 85 days (range 38--107 days).

Fifteen patients (15/53, 28.3%) discontinued the study medication before cycle 6: thirteen patients owing to AEs, mainly neuropathy (eleven patients); one patient owing to non-compliance; and one patient withdrew consent.

One patient continued to receive treatment after the cut-off date for analysis and received 27 treatment cycles. The data from the additional cycles were collected but not included in these analyses.

Efficacy
--------

Of the 46 patients in the primary analysis set, 17 (37%) had a confirmed ⩾50% PSA reduction from baseline, demonstrating that this study met its primary end point ([Figure 1](#fig1){ref-type="fig"}).

In the full analysis set, 40 patients had measurable disease. A total of 36 patients in the PP set had measurable disease, of whom 12 (33.3%) responded ([Table 2](#tbl2){ref-type="table"}). One patient had complete response; eleven patients had partial response. Median duration of objective response could not be calculated as only three of these responders experienced either a recurrence of the disease or disease progression during the observation period.

The duration of PSA response was analysed using the data from the 17 initial PSA responders and was estimated to be 289 days (95% confidence interval (CI): lower limit 166 -- upper limit could not be calculated) ([Figure 2](#fig2){ref-type="fig"}). Median time to PSA progression was 232 days (95% CI: lower limit 198 -- upper limit could not be calculated).

Median TTP was 168 days (95% CI: 131--232) and median PFS was 195 days (95% CI: 131--232) ([Figure 3](#fig3){ref-type="fig"}). Progression-free survival in patients with PSA response and those with objective response was 232 days (95% CI: 208--308) and 211 days (95% CI: 140--308), respectively ([Figure 4](#fig4){ref-type="fig"}). Median overall survival could not be calculated as only three patients died during the observation period.

Safety
------

All 53 patients received at least one dose of 16 mg m^−2^ sagopilone via a 3-h infusion and were therefore included in the safety analysis set. All patients reported at least one AE during the study treatment. Almost all (98.1%) of the observed AEs were drug-related.

The incidence of AEs indicating neurotoxicity was high, with 94.3% of patients (50 out of 53) reporting peripheral neuropathy during study treatment ([Table 3](#tbl3){ref-type="table"}) and \>50% (30 out of 53) still experiencing this AE at follow-up. The highest incidences of grade 3 or 4 AEs were reported for peripheral neuropathy (12 out of 53, 22.6%), pain in extremities (4 out of 53, 7.5%) and fatigue (4 out of 53, 7.5%). Grade 4 AEs were observed in single cases only (1 out of 53, 1.9%), with the exception of pulmonary embolism (2 out of 53, 3.8%). One patient developed a fatal grade 5 AE (gastrointestinal haemorrhage).

As a result of AEs, treatment was discontinued in 20 patients, 16 owing to peripheral neuropathy. At least one treatment was postponed in 17 patients (because of AEs in 15 patients). The majority of dose postponements were associated with subsequent dose reduction. Twenty patients required a dose reduction from 16 mg m^−2^ to 12 mg m^−2^, three of whom required a further dose reduction to 9 mg m^−2^. Toxicity management by dose reduction and/or dose delay facilitated drug compliance.

A total of 19 SAEs were experienced by 18.9% (10 out of 53) of patients during study treatment and/or follow-up, with pulmonary embolism the only SAE to be reported in more than one patient (two patients). In 4 of these 10 patients, at least one SAE was identified as drug-related. Three patients discontinued sagopilone owing to an SAE.

Four patients died during this study, three from progressive disease and one due to gastrointestinal haemorrhage (grade 5 AE), which was not drug-related.

Most changes in the CTCAE grade of quantitative laboratory parameters were from grade 0 to grade 1 or 2. Fifteen patients had a change to CTCAE grade 4, with the highest incidence rate of changes to CTCAE grade 4 in creatinine and low calcium levels. Creatinine levels for the three affected patients returned to normal by week 12 of the follow-up period. All other changes to CTCAE grade 4 were reported in a maximum of two patients. No clinically relevant changes were observed in heart rate or blood pressure.

Discussion
==========

The results of this trial clearly demonstrate that sagopilone has clinical activity in patients with CRPC. In our study, PSA reduction, measurable disease response and TTP are generally comparable to those observed in chemotherapy-naïve patients following docetaxel treatment ([@bib15]; [@bib3]). Progression-free survival was similar for both the PSA responders and the objective responders, suggesting concordance, with respect to this measurement, across these two groups.

Recognising the limitations of this small, single-arm, phase II study, measurable disease response in 1 out of 3 patients (33%) represents a relatively high level of activity, although this could be a chance finding.

In the absence of docetaxel, these results would support phase III evaluation. However, while positive, our efficacy and safety results are probably insufficiently compelling to support a head-to-head challenge against docetaxel, in the context of currently available treatment options.

The toxicity profile was notable in our study. Peripheral neuropathy was common and frequently resulted in the discontinuation of study medication. Diarrhoea, however, was relatively uncommon and haematological, and hepatic and renal toxicity were nearly absent. Given the relatively encouraging level of anti-tumour activity observed, strategies to prevent, reduce or mitigate the neuropathy were considered. Other than conventional, symptomatic management of neuropathy, which masks some of the symptoms but does not address the underlying pathological process, no additional viable methods were found to adequately address this toxicity. In this study, detailed data on the treatment administered to manage neuropathy and its outcomes were not collected.

The measurable disease response rate in the study is encouraging and all other measures are competitive. However, the potential development of neuropathy may limit the ability to deliver sagopilone for at least nine cycles, as with docetaxel in the phase III setting ([@bib20]). Therefore, overall results do not support further phase III development of sagopilone in patients with CRPC.

The recent success of second-line cabazitaxel is a reminder that successful strategies to target microtubules in PC do not start and end with docetaxel ([@bib6]). In view of the promising level of activity observed in our trial, investigation of sagopilone in docetaxel-treated patients would be of interest. Sagopilone may provide a clinically meaningful level of activity for these patients as it was developed to be unaffected by multidrug-resistance-mediated mechanisms and has demonstrated activity in taxane-resistant preclinical models ([@bib13]; [@bib10]).

Although the landscape for treating advanced PC is changing, there remains a significant need to identify and develop new cytotoxic agents for treating CRPC. Only cabazitaxel has been added to the chemotherapy armamentarium since the approval of docetaxel in 2004. Efforts have been directed towards evaluating the role of epothilones in metastatic CRPC, and to date two epothilones, ixabepilone and patupilone, have been investigated for the treatment of this disease ([@bib8]; [@bib12], [@bib11]; [@bib5]). In a phase II study, weekly patupilone (2.5 mg m^−2^) showed minimal activity in patients with PC ([@bib11]), although response improved with 3-weekly patupilone (8 mg m^−2^) in a second phase II study ([@bib5]). More robust activity was seen with ixabepilone, although this was not significantly different from that observed with docetaxel ([@bib8]; [@bib12]).

The PSA response rate and PFS observed in our sagopilone study are comparable to those reported for ixabepilone and patupilone ([@bib8]; [@bib12]; [@bib5]). Differences between these compounds are more evident in the toxicity profiles: neutropenia and neuropathy associated with ixabepilone ([@bib8]; [@bib12]), diarrhoea associated with patupilone ([@bib5]), and neuropathy associated with sagopilone. Patupilone may present an alternative to cabazitaxel, but perhaps only for patients with significant residual haematological toxicity following docetaxel. Our study adds to the limited experience with epothilone treatment for PC and, when taken in context with patupilone and ixabepilone, suggests that although this class of drugs has clinical activity, when applied to the broad CRPC population, epothilones are unlikely to significantly influence the outcomes of patients with advanced PC. Overall, it is difficult to envisage a place for any of these treatments in the current treatment landscape for PC, in which there has been considerable change recently.

However, the relatively high measurable disease response rate seen in our trial is interesting and merits further investigation. As our understanding of the heterogeneity of advanced PC increases at both molecular and clinical levels, we may learn that various subsets of PC respond differently to microtubule-targeted agents. Following the observation of a higher than expected response rate in measurable disease, clinical research efforts are currently underway to examine taxane--platinum combinations in the relatively ill-defined entity of 'anaplastic\' CRPC, a subset of patients with a proclivity to develop soft-tissue metastases. Further investigations may be justified to evaluate whether sagopilone could be a more suitable microtubule disassembly inhibitor in this subset. In the study reported in this manuscript, a high proportion of patients had a dose reduction from 16 mg m^−2^, suggesting that a lower starting dose of sagopilone should be considered.

In conclusion, we have demonstrated with PSA and measurable disease response rates a significant level of anti-tumour activity for sagopilone in patients with CRPC. The frequency of neuropathy was relatively high, distinctive and dose-limiting, and discourages further development. Moreover, the fact that the overall activity is comparable to that of docetaxel suggests that a head-to-head comparison with docetaxel in chemotherapy-naïve CRPC is probably not justified. On the other hand, a drug with this level of activity deserves further evaluation in the second-line setting and for different patient subsets to acquire a better understanding of which patients may derive greater benefit from either taxanes or epothilones.
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###### Patient demographics and baseline disease characteristics

  **Characteristics**                                      **Patients,** ***n*****=53**
  -------------------------------------------------------- ------------------------------
  Age (years), median (range)                              66 (48--86)
                                                            
  *Ethnicity*, n *(%)*                                     
   Caucasian                                               41 (77.4)
   Black                                                   6 (11.3)
   Hispanic                                                6 (11.3)
                                                            
  *WHO performance status*, n *(%)*                        
   0 or 1                                                  49 (92.5)
   2                                                       4 (7.5)
                                                            
  *Gleason score*[a](#t1-fn2){ref-type="fn"}               
   ⩽7                                                      23 (43)
   \>7                                                     28 (53)
  PSA at baseline, median (range), ng ml^−1^               106 (6--1727)
                                                            
  *Prior therapy*                                          
   Surgery, *n* (%)                                        36 (67.9)
   Radiotherapy, *n* (%)                                   31 (58.5)
   Hormonal therapy, *n* (%)[b](#t1-fn3){ref-type="fn"}    53 (100)
                                                            
  *Disease status*, n *(%)*                                
   Measurable disease[c](#t1-fn4){ref-type="fn"}           40 (75.5)
   Metastases[d](#t1-fn5){ref-type="fn"}                   48 (90.6)
                                                            
  *Location of target lesion*[e](#t1-fn6){ref-type="fn"}   
   Lymph node[f](#t1-fn7){ref-type="fn"}                   32 (91)
   Lung                                                    3 (9)
   Liver                                                   3 (9)
   Retroperitoneal mass                                    2 (6)
   Bone                                                    1 (3)
   Mediastinum                                             1 (3)
   Adrenal gland                                           1 (3)
   Pelvic mass                                             1 (3)
   Other                                                   3 (9)

Abbreviations: PSA=prostate-specific antigen; WHO=World Health Organization.

Data missing for two patients.

Patients received a median of two prior hormonal regimens.

Forty patients with measurable disease in the full analysis set.

Staging data are missing for 5 patients (9.4%).

Data available for 35 patients. Patients may have ⩾1 target lesion.

Includes superficial, pelvic, abdominal, para-aortic, mediastinal, and hilar lymph nodes.

###### Response rates, according to modRECIST, for patients with measurable disease in the per protocol set

  **modRECIST response**                        **Patients,** ***n*** **(%)**
  -------------------------------------------- -------------------------------
  Evaluable patients with measurable disease                 36
  Confirmed complete response                              1 (2.8)
  Confirmed partial response                              11 (30.6)
  Stable disease                                          16 (44.4)
  Progressive disease                                     4 (11.1)
  Unknown/not determined                                  4 (11.1)

Abbreviation: modRECIST=modified Response Evaluation Criteria in Solid Tumours.

###### Most frequently reported adverse events (\>10% of all patients) at end of study

  **Patients,** ***n*** **(%)**   **Grade 1 or 2** ***n*****=53**   **Grade 3 or 4** ***n*****=53**   **All grades** ***n*****=53**
  ------------------------------- --------------------------------- --------------------------------- -------------------------------
  Any adverse event               22 (41.5)                         30 (56.6)                         53 (100)
  Peripheral neuropathy           38 (71.7)                         12 (22.6)                         50 (94.3)
  Fatigue                         25 (47.1)                         4 (7.5)                           29 (54.7)
  Pain in extremity               21 (39.6)                         4 (7.5)                           25 (47.2)
  Arthralgia                      17 (32.0)                         1 (1.9)                           18 (34.0)
  Constipation                    13 (24.5)                         ---                               13 (24.5)
  Nausea                          13 (24.5)                         ---                               13 (24.5)
  Muscular weakness               10 (18.9)                         1 (1.9)                           11 (20.8)
  Diarrhoea                       9 (17.0)                          1 (1.9)                           10 (18.9)
  Insomnia                        10 (18.9)                         ---                               10 (18.9)
  Myalgia                         9 (17.0)                          1 (1.9)                           10 (18.9)
  Peripheral oedema               9 (17.0)                          ---                               9 (17.0)
  Asthenia                        8 (15.1)                          1 (1.9)                           9 (17.0)
  Dizziness                       7 (13.2)                          1 (1.9)                           8 (15.1)
  Alopecia                        7 (13.2)                          ---                               7 (13.2)
  Pain                            5 (9.4)                           1 (1.9)                           6 (11.3)
  Back pain                       3 (5.7)                           3 (5.7)                           6 (11.3)
  Muscle spasms                   5 (9.4)                           1 (1.9)                           6 (11.3)
  Headache                        6 (11.3)                          ---                               6 (11.3)
